Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk

Dow Jones

04/29

0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

April 29, 2026 02:59 ET (06:59 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2631569798"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2631569798\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2631569798?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-29 14:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2631569798","market":"sh","top_or_hot":-1,"title":"Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 02:59 ET (06:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCochlear Bull Thinks Volume Pressures Are Cyclical -- Market Talk\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-04-29 14:59</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 29, 2026 02:59 ET (06:59 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COH.AU","symbol_name":"COCHLEAR LTD","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2631569798","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2631569798","pubTimestamp":1777445940,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COH.AU":"COCHLEAR LTD","BK7007":"医疗保健设备"},"translate_title":"耳蜗牛市认为成交量压力是周期性的——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COH.AU":0.9},"content_text":"0659 GMT - Cochlear's bull at Jefferies doesn't think the volume pressures experienced by the hearing-implant maker are structural. Maintaining a buy rating on the stock, analyst David Stanton tells clients in a note that rising U.S. Medicare costs and authorization procedures from commercial insurers are delaying volume demand for the Australia-listed company. Most Americans with private insurers are on high-deductable plans, while the growing view among patients and insurers is that cochlear implant procedures are semielective, he adds. However, he says the market remains underpenetrated and Cochlear's volume opportunity is large. Soft demand might be extended but it is merely cyclical, he believes. Jefferies has a A$137.00 target price on the stock, which closed 3.2% lower at A$90.00. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 29, 2026 02:59 ET (06:59 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}